Answer:
1. As part of the FDA, the Center for Drug Evaluation and Research (CDER) applies several internal procedures to evaluate the possibility of a brand name before its marketing to avoid medication errors attributed to different items having the same name and by doing so, guarantee the safe use of drugs.
Step-by-step explanation:
2. They did it because it's mandated by the FDA, and the possibility of a full product recall would be much more costly than rebranding the product.
3. The company had to pay for the rebranding process, but avoided a more costly recalls pocess. They provably learned how important it´s to have a regulatory counsel involved in the branding activities.